Candida auris, the fungus that shall not be named

1] Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I. (2002). The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. The American journal of medicine, 112(5), 380–385. [2] Hasan, F., Xess, I., Wang, X., Jain, N., & Fries, B. C. (2009). Biofilm formation in clinical Candida isolates and its association with virulence. Microbes and infection, 11(8-9), 753–761. [3] Sardi, J. d. C. O., Silva, D. R., Mendes-Giannini, M. J. S., & Rosalen, P. L. (2018). Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options. Microbial pathogenesis, 125, 116–121. [4] Fidel Jr, P. L., Vazquez, J. A., & Sobel, J. D. (1999). Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to c. albicans. Clinical microbiology reviews, 12(1), 80–96. [5] Spivak, E. S., & Hanson, K. E. (2018). Candida auris: An emerging fungal pathogen. Journal of clinical microbiology, 56(2), e01588–17. [6] Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009). Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a japanese hospital. Microbiology and immunology, 53(1), 41–44. [7] Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011). First three reported cases of nosocomial fungemia caused by Candida auris. Journal of clinical microbiology, 49(9), 3139–3142. [8] Corsi-Vasquez, G., & Ostrosky-Zeichner, L. (2019). Candida auris: What have we learned so far? Current opinion in infectious diseases, 32(6), 559–564. [9] Chybowska, A. D., Childers, D. S., & Farrer, R. A. (2020). Nine things genomics can tell us about Candida auris. Frontiers in genetics, 11, 351. [10] Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017). Multidrug-resistant Candida haemulonii and c. auris, tel aviv, israel. Emerging infectious diseases, 23(2), 195. [11] Guarie, M. (n.d.). What is candida auris. https://www.verywellhealth.com/candida-auris-4692475 (accessed: 02.06.2022) [12] Nett, J. E. (2019). Candida auris: An emerging pathogen “incognito”? PLoS pathogens, 15(4), e1007638. [13] Casadevall, A., Kontoyiannis, D. P., & Robert, V. (2019). On the emergence of candida auris: Climate change, azoles, swamps, and birds. MBio, 10(4), e01397–19. [14] Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017). Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Diseases, 64(2), 134–140. [15] Rhodes, J., & Fisher, M. C. (2019). Global epidemiology of emerging Candida auris. Current opinion in microbiology, 52, 84–89. [16] Chow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., Barrett, P. M., Kerins, J. L., Lockhart, S. R., Chiller, T. M., et al. (2018). Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the usa: A molecular epidemiological survey. The Lancet Infectious diseases, 18(12), 1377–1384. [17] Chow, N. A., Muñoz, J. F., Gade, L., Berkow, E. L., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020). Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses. MBio, 11(2), e03364–19. [18] Welsh, R. M., Sexton, D. J., Forsberg, K., Vallabhaneni, S., & Litvintseva, A. (2019). Insights into the unique nature of the east asian clade of the emerging pathogenic yeast Candida auris. Journal of Clinical Microbiology, 57(4), e00007–19. [19] Chow, N. A., de Groot, T., Badali, H., Abastabar, M., Chiller, T. M., & Meis, J. F. (2019). Potential fifth clade of Candida auris, iran, 2018. Emerging infectious diseases, 25(9), 1780. [20] Lone, S. A., & Ahmad, A. (2019). Candida auris—the growing menace to global health. Mycoses, 62(8), 620–637. [21] Szekely, A., Borman, A. M., & Johnson, E. M. (2019). Candida auris isolates of the southern asian and south african lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. Journal of Clinical Microbiology, 57(5), e02055–18. [22] Kohlenberg, A., Struelens, M. J., Monnet, D. L., Plachouras, D., et al. (2018). Candida auris: Epidemiological situation, laboratory capacity and preparedness in european union and european economic area countries, 2013 to 2017. Eurosurveillance, 23(13), 18–00136. [23] Gaitán, A. C. R., Moret, A., Hontangas, J. L. L., Molina, J. M., López, A. I. A., Cabezas, A. H., Maseres, J. M., Arcas, R. C., Ruiz, M. D. G., Chiveli, M. Á., et al. (2017). Nosocomial fungemia by Candida auris: First four reported cases in continental europe. Revista iberoamericana de micologia, 34(1), 23–27. [24] Calvo, B., Melo, A. S., Perozo-Mena, A., Hernandez, M., Francisco, E. C., Hagen, F., Meis, J. F., & Colombo, A. L. (2016). First report of Candida auris in america: Clinical and microbiological aspects of 18 episodes of candidemia. Journal of Infection, 73(4), 369–374. [25] Schwartz, I., & Hammond, G. (2017). Outbreak detection: First reported case of multidrug-resistant Candida auris in canada. Canada Communicable Disease Report, 43(7-8), 150. 87 [26] Araúz, A. B., Caceres, D. H., Santiago, E., Armstrong, P., Arosemena, S., Ramos, C., Espinosa-Bode, A., Borace, J., Hayer, L., Cedeño, I., et al. (2018). Isolation of Candida auris from 9 patients in central america: Importance of accurate diagnosis and susceptibility testing. Mycoses, 61(1), 44–47. [27] Heath, C. H., Dyer, J. R., Pang, S., Coombs, G. W., & Gardam, D. J. (2019). Candida auris sternal osteomyelitis in a man from kenya visiting australia, 2015. Emerging infectious diseases, 25(1), 192. [28] Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017). The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals, and effect of scy-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrobial agents and chemotherapy, 61(5), e02396–16. [29] Ahmad, A., Spencer, J. E., Lockhart, S. R., Singleton, S., Petway, D. J., Bagarozzi Jr, D. A., & Herzegh, O. T. (2019). A high-throughput and rapid method for accurate identification of emerging multidrug-resistant Candida auris. Mycoses, 62(6), 513–518. [30] Wattal, C., Oberoi, J., Goel, N., Raveendran, R., & Khanna, S. (2017). Matrix-assisted laser desorption ionization time of flight mass spectrometry (maldi-tof ms) for rapid identification of micro-organisms in the routine clinical microbiology laboratory. European Journal of Clinical Microbiology & Infectious Diseases, 36(5), 807–812. [31] Bao, J. R., Master, R. N., Azad, K. N., Schwab, D. A., Clark, R. B., Jones, R. S., Moore, E. C., & Shier, K. L. (2018). Rapid, accurate identification of Candida auris by using a novel matrix-assisted laser desorption ionization–time of flight mass spectrometry (maldi-tof ms) database (library). Journal of clinical microbiology, 56(4), e01700–17. [32] Eyre, D. W., Sheppard, A. E., Madder, H., Moir, I., Moroney, R., Quan, T. P., Griffiths, D., George, S., Butcher, L., Morgan, M., et al. (2018). A Candida auris outbreak and its control in an intensive care setting. New England Journal of Medicine, 379(14), 1322–1331. [33] Ku, T. S., Walraven, C. J., & Lee, S. A. (2018). Candida auris: Disinfectants and implications for infection control. Frontiers in microbiology, 9, 726. [34] Chowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018). A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in india: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 73(4), 891–899. [35] Fromtling, R. A. (1988). Overview of medically important antifungal azole derivatives. Clinical microbiology reviews, 1(2), 187–217. [36] Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020). Candidiasis and mechanisms of antifungal resistance. Antibiotics, 9(6), 312. [37] Kodedová, M., & Sychrová, H. (2015). Changes in the sterol composition of the plasma membrane affect membrane potential, salt tolerance and the activity of multidrug resistance pumps in Saccharomyces cerevisiae. PLoS One, 10(9), e0139306. [38] Mollinedo, F. (2012). Lipid raft involvement in yeast cell growth and death. Frontiers in oncology, 2, 140. [39] Dupont, S., Fleurat-Lessard, P., Cruz, R. G., Lafarge, C., Grangeteau, C., Yahou, F., Gerbeau-Pissot, P., Abrahão Júnior, O., Gervais, P., SimonPlas, F., et al. (2021). Antioxidant properties of ergosterol and its role in yeast resistance to oxidation. Antioxidants, 10(7), 1024. [40] Bhattacharya, S., Esquivel, B. D., & White, T. C. (2018). Overexpression or deletion of ergosterol biosynthesis genes alters doubling time, response to stress agents, and drug susceptibility in Saccharomyces cerevisiae. MBio, 9(4), e01291–18. [41] Sanglard, D., Coste, A., & Ferrari, S. (2009). Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS yeast research, 9(7), 1029–1050. [42] Francois, I. E., Cammue, B., Borgers, M., Ausma, J., Dispersyn, G. D., & Thevissen, K. (2006). Azoles: Mode of antifungal action and resistance development. effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Infective Agents), 5(1), 3–13. [43] Delattin, N., Cammue, B. P., & Thevissen, K. (2014). Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future medicinal chemistry, 6(1), 77–90. [44] Caballero, U., Kim, S., Eraso, E., Quindós, G., Vozmediano, V., Schmidt, S., & Jauregizar, N. (2021). In vitro synergistic interactions of isavuconazole and echinocandins against Candida auris. Antibiotics, 10(4), 355. [45] Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018). Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrobial agents and chemotherapy, 62(6), e00238–18. [46] Grover, N. D. (2010). Echinocandins: A ray of hope in antifungal drug therapy. Indian journal of pharmacology, 42(1), 9. [47] Perlin, D. S. (2007). Resistance to echinocandin-class antifungal drugs. Drug Resistance Updates, 10(3), 121–130. [48] Cândido, E. d. S., Affonseca, F., Cardoso, M. H., & Franco, O. L. (2020). Echinocandins as biotechnological tools for treating Candida auris infections. Journal of Fungi, 6(3), 185. [49] Kovács, R., Tóth, Z., Locke, J. B., Forgács, L., Kardos, G., Nagy, F., Borman, A. M., & Majoros, L. (2021). Comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in rpmi-1640 in the absence and presence of human serum. Microorganisms, 9(4), 863. 88 [50] Pfaller, M., Boyken, L., Hollis, R., Messer, S., Tendolkar, S., & Diekema, D. (2006). Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by clsi-recommended methods. Journal of clinical microbiology, 44(10), 3533–3538. [51] Tóth, Z., Forgács, L., Kardos, T., Kovács, R., Locke, J. B., Kardos, G., Nagy, F., Borman, A. M., Adnan, A., & Majoros, L. (2020). Relative frequency of paradoxical growth and trailing effect with caspofungin, micafungin, anidulafungin, and the novel echinocandin rezafungin against Candida species. Journal of Fungi, 6(3), 136. [52] Carolus, H., Pierson, S., Lagrou, K., & Van Dijck, P. (2020). Amphotericin b and other polyenes—discovery, clinical use, mode of action and drug resistance. Journal of Fungi, 6(4), 321. [53] Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., & Burke, M. D. (2012). Amphotericin primarily kills yeast by simply binding ergosterol. Proceedings of the National Academy of Sciences, 109(7), 2234–2239. [54] Kamiński, D. M. (2014). Recent progress in the study of the interactions of amphotericin b with cholesterol and ergosterol in lipid environments. European biophysics journal, 43(10), 453–467. [55] Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., et al. (2014). Amphotericin forms an extramembranous and fungicidal sterol sponge. Nature chemical biology, 10(5), 400–406. [56] Dutcher, J. D. (1968). The discovery and development of amphotericin b. Diseases of the Chest, 54, 296–298. [57] Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003). Amphotericin b: Time for a new “gold standard”. Clinical Infectious Diseases, 37(3), 415–425. [58] Duschinsky, R., Pleven, E., & Heidelberger, C. (1957). The synthesis of 5-fluoropyrimidines. Journal of the American Chemical Society, 79(16), 4559–4560. [59] Titsworth, E., & Grunberg, E. (1973). Chemotherapeutic activity of 5-fluorocytosine and amphotericin b against Candida albicans in mice. Antimicrobial Agents and Chemotherapy, 4(3), 306–308. [60] Tassel, D., & Madoff, M. A. (1968). Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine: A new antifungal agent. Jama, 206(4), 830–832. [61] Mayers, D. L., Sobel, J. D., Ouellette, M., Kaye, K. S., & Marchaim, D. (2009). Antimicrobial drug resistance. Springer. [62] Vermes, A., Guchelaar, H.-J., & Dankert, J. (2000). Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy, 46(2), 171–179. [63] Polak, A., & Scholer, H. (1975). Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy, 21(3-4), 113–130. [64] Waldorf, A. R., & Polak, A. (1983). Mechanisms of action of 5-fluorocytosine. Antimicrobial Agents and Chemotherapy, 23(1), 79–85. [65] INC, S. (n.d.). Ibrexafungerp (formerly scy-078). https://www.scynexis.com/pipeline (accessed: 09.12.2021) [66] Jallow, S., & Govender, N. P. (2021). Ibrexafungerp: A first-in-class oral triterpenoid glucan synthase inhibitor. Journal of Fungi, 7(3), 163. [67] Arendrup, M. C., Jørgensen, K. M., Hare, R. K., & Chowdhary, A. (2020). In vitro activity of ibrexafungerp (scy-078) against Candida aurisisolates as determined by eucast methodology and comparison with activity against c. albicans and c. glabrata and with the activities of six comparator agents. Antimicrobial agents and chemotherapy, 64(3), e02136–19. [68] Berkow, E. L., Angulo, D., & Lockhart, S. R. (2017). In vitro activity of a novel glucan synthase inhibitor, scy-078, against clinical isolates of Candida auris. Antimicrobial Agents and Chemotherapy, 61(7), e00435–17. [69] Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021). Ibrexafungerp, a novel oral triterpenoid antifungal in development: Overview of antifungal activity against Candida glabrata. Frontiers in cellular and infection microbiology, 11, 126. [70] Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020). Oral ibrexafungerp: An investigational agent for the treatment of vulvovaginal candidiasis. Expert Opinion on Investigational Drugs, 29(9), 893–900. [71] Sobel, R., Nyirjesy, P., Ghannoum, M. A., Delchev, D. A., Azie, N. E., Angulo, D., Harriott, I. A., Borroto-Esoda, K., & Sobel, J. D. (2022). Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: A global phase 3, randomised, placebo-controlled superiority study (vanish 306). BJOG: An International Journal of Obstetrics & Gynaecology, 129(3), 412–420. [72] Masone, M. C. (2021). Ibrexafungerp to treat acute vulvovaginal candidiasis. Nature Reviews Urology, 18(11), 638–638. [73] Wiederhold, N. P., Najvar, L. K., Olivo, M., Morris, K. N., Patterson, H. P., Catano, G., & Patterson, T. F. (2021). Ibrexafungerp demonstrates in vitro activity against fluconazole-resistant Candida auris and in vivo efficacy with delayed initiation of therapy in an experimental model of invasive candidiasis. Antimicrobial agents and chemotherapy, 65(6), e02694–20. [74] Therapeutics, A. (n.d.). A novel, broad spectrum, clinical stage antifungal to address severe and difficult-to-treat invasive fungal infections. https: //www.appilitherapeutics.com/ati-2307 [75] Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008). In vitro and in vivo antifungal activities of t-2307, a novel arylamidine. Antimicrobial agents and chemotherapy, 52(4), 1318–1324. 89 [76] Cohen, A., & Brown, S. (n.d.). Appili therapeutics acquires clinical stage antifungal program from fujifilm toyama chemical. https : / / www . businesswire.com/news/home/20191121005346/en/Appili - Therapeutics - Acquires - Clinical - Stage - Antifungal - Program - From - FUJIFILM - Toyama-Chemical [77] Gerlach, E. S., Altamirano, S., Yoder, J. M., Luggya, T. S., Akampurira, A., Meya, D. B., Boulware, D. R., Rhein, J., & Nielsen, K. (2021). Ati-2307 exhibits equivalent antifungal activity in Cryptococcus neoformans clinical isolates with high and low fluconazole ic50. Frontiers in Cellular and Infection Microbiology, 11. [78] Nolan, E. (n.d.). Pfizer acquires amplyx pharmaceuticals. https://www.businesswire.com/news/home/20210428005147/en/Pfizer- AcquiresAmplyx-Pharmaceuticals (accessed: 10.12.2021) [79] Petraitiene, R., Petraitis, V., Maung, B. B. W., Mansbach, R. S., Hodges, M. R., Finkelman, M. A., Shaw, K. J., & Walsh, T. J. (2021). Efficacy and pharmacokinetics of fosmanogepix (apx001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits. Antimicrobial Agents and Chemotherapy, 65(3), e01795–20. [80] Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021). The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs, 81(15), 1703–1729. [81] Shaw, K. J., & Ibrahim, A. S. (2020). Fosmanogepix: A review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. Journal of Fungi, 6(4), 239. [82] Watanabe, N.-a., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012). E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrobial agents and chemotherapy, 56(2), 960–971. [83] Kim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020). Antifungal drug repurposing. Antibiotics, 9(11), 812. [84] De Oliveira, H. C., Monteiro, M. C., Rossi, S. A., Pemán, J., Ruiz-Gaitán, A., Mendes-Giannini, M. J. S., Mellado, E., & Zaragoza, O. (2019). Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris. Frontiers in Cellular and Infection Microbiology, 9, 83. [85] Wall, G., Herrera, N., & Lopez-Ribot, J. L. (2019). Repositionable compounds with antifungal activity against multidrug resistant Candida auris identified in the medicines for malaria venture’s pathogen box. Journal of Fungi, 5(4), 92. [86] Wall, G., Chaturvedi, A. K., Wormley Jr, F. L., Wiederhold, N. P., Patterson, H. P., Patterson, T. F., & Lopez-Ribot, J. L. (2018). Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development. Antimicrobial agents and chemotherapy, 62(10), e01084–18. [87] Goncalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., & Colombo, A. L. (2016). Epidemiology and molecular mechanisms of antifungal resistance in candida and aspergillus. Mycoses, 59(4), 198–219. [88] Lockhart, S. R. (2019). Candida auris and multidrug resistance: Defining the new normal. Fungal Genetics and Biology, 131, 103243. [89] Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015). Mechanisms of antifungal drug resistance. Cold Spring Harbor perspectives in medicine, 5(7), a019752. [90] Berkow, E. L., & Lockhart, S. R. (2017). Fluconazole resistance in candida species: A current perspective. Infection and drug resistance, 10, 237. [91] Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020). Mutations in TAC1b: A novel genetic determinant of clinical fluconazole resistance in Candida auris. MBio, 11(3), e00365–20. [92] Li, J., Coste, A. T., Liechti, M., Bachmann, D., Sanglard, D., & Lamoth, F. (2021). Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris. Antimicrobial agents and chemotherapy, 65(5), e02663–20. [93] Rybak, J. M., Doorley, L. A., Nishimoto, A. T., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2019). Abrogation of triazole resistance upon deletion of CDR11 in a clinical isolate of Candida auris. Antimicrobial agents and chemotherapy, 63(4), e00057–19. [94] Wasi, M., Khandelwal, N. K., Moorhouse, A. J., Nair, R., Vishwakarma, P., Bravo Ruiz, G., Ross, Z. K., Lorenz, A., Rudramurthy, S. M., Chakrabarti, A., et al. (2019). Abc transporter genes show upregulated expression in drug-resistant clinical isolates of Candida auris: A genomewide characterization of atp-binding cassette (abc) transporter genes. Frontiers in microbiology, 1445. [95] Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrı́o, I., Chowdhary, A., & Perlin, D. S. (2018). Limited ERG11 mutations identified in isolates of Candida auris directly contribute to reduced azole susceptibility. Antimicrobial agents and chemotherapy, 62(10), e01427– 18. [96] Morio, F., Pagniez, F., Lacroix, C., Miegeville, M., & Le Pape, P. (2012). Amino acid substitutions in the Candida albicans sterol ∆5, 6-desaturase (erg3p) confer azole resistance: Characterization of two novel mutants with impaired virulence. Journal of antimicrobial chemotherapy, 67(9), 2131–2138. 90 [97] Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012). Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryotic cell, 11(10), 1289–1299. [98] Bing, J., Hu, T., Zheng, Q., Muñoz, J. F., Cuomo, C. A., & Huang, G. (2020). Experimental evolution identifies adaptive aneuploidy as a mechanism of fluconazole resistance in Candida auris. Antimicrobial agents and chemotherapy, 65(1), e01466–20. [99] Carolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2020). Genome-wide analysis of experimentally evolved Candida auris reveals multiple novel mechanisms of multidrug-resistance. bioRxiv. [100] Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K., Karim, S., Singh, S., Hagen, F., et al. (2014). Multidrug-resistant endemic clonal strain of Candida auris in india. European journal of clinical microbiology & infectious diseases, 33(6), 919–926. [101] Larsen, R. A. (2011). Flucytosine. In Essentials of clinical mycology (pp. 57–60). Springer. [102] Garcia-Effron, G., Park, S., & Perlin, D. S. (2009). Correlating echinocandin mic and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints. Antimicrobial agents and chemotherapy, 53(1), 112–122. [103] Perlin, D. S. (2015). Echinocandin resistance in Candida. Clinical Infectious Diseases, 61(suppl_6), S612–S617. [104] Cortegiani, A., Misseri, G., Fasciana, T., Giammanco, A., Giarratano, A., & Chowdhary, A. (2018). Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. Journal of intensive care, 6(1), 1–13. [105] Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009). Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-β-d-glucan synthase: Implication for the existing susceptibility breakpoint. Antimicrobial agents and chemotherapy, 53(9), 3690–3699. [106] Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008). Mutations in the FKS1 gene in Candida albicans, c. tropicalis, and c. krusei correlate with elevated caspofungin mics uncovered in am3 medium using the method of the european committee on antibiotic susceptibility testing. Antimicrobial agents and chemotherapy, 52(9), 3092–3098. [107] Walker, L. A., Munro, C. A., De Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. (2008). Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS pathogens, 4(4), e1000040. [108] Sharma, D., Paul, R. A., Rudramurthy, S. M., Kashyap, N., Bhattacharya, S., Soman, R., Shankarnarayan, S. A., Chavan, D., Singh, S., Das, P., et al. (2021). Impact of FKS1 genotype on echinocandin in vitro susceptibility in Candida auris and in vivo response in a murine model of infection. Antimicrobial Agents and Chemotherapy, 66(1), e01652–21. [109] Ben-Ami, R., Garcia-Effron, G., Lewis, R. E., Gamarra, S., Leventakos, K., Perlin, D. S., & Kontoyiannis, D. P. (2011). Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. Journal of Infectious Diseases, 204(4), 626–635. [110] Munro, C. A., Selvaggini, S., De Bruijn, I., Walker, L., Lenardon, M. D., Gerssen, B., Milne, S., Brown, A. J., & Gow, N. A. (2007). The pkc, hog and ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Molecular microbiology, 63(5), 1399–1413. [111] Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019). Fungal cell wall: Emerging antifungals and drug resistance. Frontiers in microbiology, 2573. [112] Stover, K. R., & Cleary, J. D. (2015). The eagle-like effect of the echinocandins: Is it relevant for clinical decisions? Current Fungal Infection Reports, 9(2), 88–93. [113] Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013). Fitness trade-offs restrict the evolution of resistance to amphotericin b. PLoS biology, 11(10), e1001692. [114] Geber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., & Bennett, J. E. (1995). Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrobial Agents and Chemotherapy, 39(12), 2708–2717. [115] Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003). Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrobial agents and chemotherapy, 47(8), 2404–2412. [116] Young, L. Y., Hull, C. M., & Heitman, J. (2003). Disruption of ergosterol biosynthesis confers resistance to amphotericin b in Candida lusitaniae. Antimicrobial agents and chemotherapy, 47(9), 2717–2724. [117] Phillips, A. J., Sudbery, I., & Ramsdale, M. (2003). Apoptosis induced by environmental stresses and amphotericin b in Candida albicans. Proceedings of the National Academy of Sciences, 100(24), 14327–14332. [118] LAMP-FREUND, M. T., FERREIRA, V. F., & SCHREIER, S. (1985). Mechanism of inactivation of the polyene antibiotic amphotericin b evidence for radical formation in the process of autooxidation. The Journal of antibiotics, 38(6), 753–757. 91 [119] Sangalli-Leite, F., Scorzoni, L., Mesa-Arango, A. C., Casas, C., Herrero, E., Gianinni, M. J. S. M., Rodrı́guez-Tudela, J. L., Cuenca-Estrella, M., & Zaragoza, O. (2011). Amphotericin b mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes and infection, 13(5), 457–467. [120] Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017). The global problem of antifungal resistance: Prevalence, mechanisms, and management. The Lancet infectious diseases, 17(12), e383–e392. [121] Blum, G., Perkhofer, S., Haas, H., Schrettl, M., Würzner, R., Dierich, M. P., & Lass-Flörl, C. (2008). Potential basis for amphotericin b resistance in aspergillus terreus. Antimicrobial agents and chemotherapy, 52(4), 1553–1555. [122] Posch, W., Blatzer, M., Wilflingseder, D., & Lass-Flörl, C. (2018). Aspergillus terreus: Novel lessons learned on amphotericin b resistance. Medical Mycology, 56(suppl_1), S73–S82. [123] Kaloriti, D., Jacobsen, M., Yin, Z., Patterson, M., Tillmann, A., Smith, D. A., Cook, E., You, T., Grimm, M. J., Bohovych, I., et al. (2014). Mechanisms underlying the exquisite sensitivity of Candida albicans to combinatorial cationic and oxidative stress that enhances the potent fungicidal activity of phagocytes. MBio, 5(4), e01334–14. [124] Zhang, X., De Micheli, M., Coleman, S. T., Sanglard, D., & Moye-Rowley, W. S. (2000). Analysis of the oxidative stress regulation of the Candida albicans transcription factor, cap1p. Molecular microbiology, 36(3), 618–629. [125] Brown, A. J., Budge, S., Kaloriti, D., Tillmann, A., Jacobsen, M. D., Yin, Z., Ene, I. V., Bohovych, I., Sandai, D., Kastora, S., et al. (2014). Stress adaptation in a pathogenic fungus. Journal of Experimental Biology, 217(1), 144–155. [126] Pál, C., Papp, B., & Lázár, V. (2015). Collateral sensitivity of antibiotic-resistant microbes. Trends in microbiology, 23(7), 401–407. [127] Efferth, T., Saeed, M. E., Kadioglu, O., Seo, E.-J., Shirooie, S., Mbaveng, A. T., Nabavi, S. M., & Kuete, V. (2020). Collateral sensitivity of natural products in drug-resistant cancer cells. Biotechnology advances, 38, 107342. [128] Imamovic, L., & Sommer, M. O. (2013). Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Science translational medicine, 5(204), 204ra132–204ra132. [129] Szybalski, W., & Bryson, V. (1952). Genetic studies on microbial cross resistance to toxic agents i., cross resistance of Escherichia coli to fifteen antibiotics. Journal of bacteriology, 64(4), 489–499. [130] Roemhild, R., & Andersson, D. I. (2021). Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathogens, 17(1), e1009172. [131] Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resistance Updates, 15(1-2), 98–105. [132] Lázár, V., Pal Singh, G., Spohn, R., Nagy, I., Horváth, B., Hrtyan, M., Busa-Fekete, R., Bogos, B., Méhi, O., Csörgő, B., et al. (2013). Bacterial evolution of antibiotic hypersensitivity. Molecular systems biology, 9(1), 700. [133] Griffith, J. K., Kogoma, T., Corvo, D. L., Anderson, W. L., & Kazim, A. (1988). An n-terminal domain of the tetracycline resistance protein increases susceptibility to aminoglycosides and complements potassium uptake defects in Escherichia coli. Journal of bacteriology, 170(2), 598–604. [134] Merlin, T., Davis, G., Anderson, W., Moyzis, R., & Griffith, J. (1989). Aminoglycoside uptake increased by tet gene expression. Antimicrobial agents and chemotherapy, 33(9), 1549–1552. [135] Podnecky, N. L., Fredheim, E. G., Kloos, J., Sørum, V., Primicerio, R., Roberts, A. P., Rozen, D. E., Samuelsen, Ø., & Johnsen, P. J. (2018). Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli. Nature Communications, 9(1), 1–11. [136] Apjok, G., Boross, G., Nyerges, Á., Fekete, G., Lázár, V., Papp, B., Pál, C., & Csörgő, B. (2019). Limited evolutionary conservation of the phenotypic effects of antibiotic resistance mutations. Molecular biology and evolution, 36(8), 1601–1611. [137] Barbosa, C., Römhild, R., Rosenstiel, P., & Schulenburg, H. (2019). Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen pseudomonas aeruginosa. Elife, 8, e51481. [138] Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of atp–dependent transporters. Nature reviews cancer, 2(1), 48–58. [139] Leonard, G. D., Fojo, T., & Bates, S. E. (2003). The role of abc transporters in clinical practice. The oncologist, 8(5), 411–424. [140] Fox, E., & Bates, S. E. (2007). Tariquidar (xr9576): A p-glycoprotein drug efflux pump inhibitor. Expert review of anticancer therapy, 7(4), 447–459. [141] Broxterman, H. J., Pinedo, H. M., Kuiper, C. M., Kaptein, L. C., Schuurhuis, G. J., & Lankelma, J. (1988). Induction by verapamil of a rapid increase in atp consumption in multidrug-resistant tumor cells. The FASEB Journal, 2(7), 2278–2282. [142] Karwatsky, J., Lincoln, M. C., & Georges, E. (2003). A mechanism for p-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry, 42(42), 12163–12173. [143] Laberge, R.-M., Ambadipudi, R., & Georges, E. (2009). P-glycoprotein (abcb1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. Archives of biochemistry and biophysics, 491(1-2), 53–60. 92 [144] Shutt, D., O’Dorisio, M. S., Aykin-Burns, N., & Spitz, D. (2010). 2-deoxy-d-glucose induces oxidative stress and cell killing in human neuroblastoma cells. Cancer biology & therapy, 9(11), 853–861. [145] Fath, M. A., Diers, A. R., Aykin-Burns, N., Simons, A. L., Hua, L., & Spitz, D. R. (2009). Mitochondrial electron transport chain blockers enhance 2-deoxy-d-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer biology & therapy, 8(13), 1228–1236. [146] Callaghan, R., & Riordan, J. R. (1995). Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1236(1), 155–162. [147] Bal, A., Kumar, A., & Gould, I. (2010). Antibiotic heterogeneity: From concept to practice. Annals of the New York Academy of Sciences, 1213(1), 81–91. [148] Niederman, M. S. (2003). Appropriate use of antimicrobial agents: Challenges and strategies for improvement. Critical care medicine, 31(2), 608–616. [149] Aulin, L., Liakopoulos, A., van der Graaf, P. H., Rozen, D. E., & van Hasselt, J. (2021). Design principles of collateral sensitivity-based dosing strategies. Nature communications, 12(1), 1–14. [150] Nowell, P. C. (1976). The clonal evolution of tumor cell populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science, 194(4260), 23–28. [151] Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—an evolving hallmark of cancer. Nature reviews Molecular cell biology, 11(3), 220–228. [152] Fisher, R., Pusztai, L., & Swanton, C. (2013). Cancer heterogeneity: Implications for targeted therapeutics. British journal of cancer, 108(3), 479–485. [153] Zhao, B., Sedlak, J. C., Srinivas, R., Creixell, P., Pritchard, J. R., Tidor, B., Lauffenburger, D. A., & Hemann, M. T. (2016). Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell, 165(1), 234–246. [154] Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse resistance? Nature Reviews Microbiology, 8(4), 260–271. [155] Ottmann, O. G., & Pfeifer, H. (2009). Management of philadelphia chromosome–positive acute lymphoblastic leukemia (ph+ all). ASH Education Program Book, 2009(1), 371–381. [156] Rex, J. H., Alexander, B. D., Andes, D., Arthington-Skaggs, B., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Espinel-Ingroff, A., Knapp, C. C., Ostrosky-Zeichner, L., Pfaller, M. A., Sheehan, D. J., & Walsh, T. J. (2008). Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard - third edition. Clinical and Laboratory Standards Institute (CLSI). [157] inc., N. E. B. (n.d.). Tm calculator. https://tmcalculator.neb.com/#!/main [158] Eurofins. (n.d.). The tubeseq service is sanger sequencing with the extra bit. https://eurofinsgenomics.eu/en/custom- dna- sequencing/eurofinsservices/tubeseq-service/ [159] Open, R. L. (n.d.). Snap2. https://rostlab.org/owiki/index.php/Snap2 (accessed: 20.07.2022) [160] Kathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015). Multidrug-resistant Candida auris misidentified as Candida haemulonii: Characterization by matrix-assisted laser desorption ionization–time of flight mass spectrometry and dna sequencing and its antifungal susceptibility profile variability by vitek 2, clsi broth microdilution, and etest method. Journal of clinical microbiology, 53(6), 1823–1830. [161] Veitch, Z. W., Guo, B., Hembruff, S. L., Bewick, A. J., Heibein, A. D., Eng, J., Cull, S., Maclean, D. A., & Parissenti, A. M. (2009). Induction of 1c aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenetics and genomics, 19(6), 477–488. [162] Björkman, J., Hughes, D., & Andersson, D. I. (1998). Virulence of antibiotic-resistant salmonella typhimurium. Proceedings of the National Academy of Sciences, 95(7), 3949–3953. [163] Maisnier-Patin, S., Berg, O. G., Liljas, L., & Andersson, D. I. (2002). Compensatory adaptation to the deleterious effect of antibiotic resistance in salmonella typhimurium. Molecular microbiology, 46(2), 355–366. [164] Gullberg, E., Cao, S., Berg, O. G., Ilbäck, C., Sandegren, L., Hughes, D., & Andersson, D. I. (2011). Selection of resistant bacteria at very low antibiotic concentrations. PLoS pathogens, 7(7), e1002158. [165] Bosch, F. v. d., Oliver, R., Berg, F. v. d., & Paveley, N. (2014). Governing principles can guide fungicide-resistance management tactics. Annual Review of Phytopathology, 52, 175–195. [166] Van Den Bosch, F., Paveley, N., Shaw, M., Hobbelen, P., & Oliver, R. (2011). The dose rate debate: Does the risk of fungicide resistance increase or decrease with dose? Plant Pathology, 60(4), 597–606. [167] van den Bosch, F., & Gilligan, C. A. (2008). Models of fungicide resistance dynamics. Annu. Rev. Phytopathol., 46, 123–147. 93 [168] Zur Wiesch, P. A., Kouyos, R., Engelstädter, J., Regoes, R. R., & Bonhoeffer, S. (2011). Population biological principles of drug-resistance evolution in infectious diseases. The Lancet infectious diseases, 11(3), 236–247. [169] Kilburn, S., Innes, G., Quinn, M., Southwick, K., Ostrowsky, B., Greenko, J. A., Lutterloh, E., Greeley, R., Magleby, R., Chaturvedi, V., et al. (2022). Antifungal resistance trends of Candida auris clinical isolates in new york and new jersey from 2016 to 2020. Antimicrobial Agents and Chemotherapy, 66(3), e02242–21. [170] for Disease Control, C., & Prevention. (n.d.). Antifungal susceptibility testing and interpretation. https://www.cdc.gov/fungal/candida-auris/cauris-antifungal.html (accessed: 29.07.2022) [171] Escandón, P., Chow, N. A., Caceres, D. H., Gade, L., Berkow, E. L., Armstrong, P., Rivera, S., Misas, E., Duarte, C., Moulton-Meissner, H., et al. (2019). Molecular epidemiology of Candida auris in colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin b resistance. Clinical Infectious Diseases, 68(1), 15–21. [172] Rybak, J. M., Barker, K. S., Muñoz, J. F., Parker, J. E., Ahmad, S., Mokaddas, E., Abdullah, A., Elhagracy, R. S., Kelly, S. L., Cuomo, C. A., et al. (2022). In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin b resistance in Candida auris. Clinical Microbiology and Infection, 28(6), 838–843. [173] Fuchs, F., Hof, H., Hofmann, S., Kurzai, O., Meis, J. F., & Hamprecht, A. (2021). Antifungal activity of nitroxoline against Candida auris isolates. Clinical Microbiology and Infection, 27(11), 1697–e7. [174] Hao, W., Wang, Y., Xi, Y., Yang, Z., Zhang, H., & Ge, X. (2022). Activity of chlorhexidine acetate in combination with fluconazole against suspensions and biofilms of Candida auris. Journal of Infection and Chemotherapy, 28(1), 29–34. [175] Betts, M. J., & Russell, R. B. (2003). Amino acid properties and consequences of substitutions. Bioinformatics for geneticists, 317, 289. [176] Berkow, E. L., & Lockhart, S. R. (2018). Activity of cd101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagnostic microbiology and infectious disease, 90(3), 196–197. [177] Roberts, S. M., & Gibb, A. J. (2013). Introduction to enzymes, receptors and the action of small molecule drugs. In Introduction to biological and small molecule drug research and development (pp. 1–55). Elsevier. [178] (SGD), S. G. D. (n.d.[a]). ERG3 / ylr056w overview. https://www.yeastgenome.org/locus/S000004046 (accessed: 20.05.2022 [179] (SGD), S. G. D. (n.d.[b]). ERG11 / yhr007c overview. https://www.yeastgenome.org/locus/S000001049 (accessed: 20.05.2022 [180] Charlier, C., El Sissy, C., Bachelier-Bassi, S., Scemla, A., Quesne, G., Sitterlé, E., Legendre, C., Lortholary, O., & Bougnoux, M.-E. (2016). Acquired flucytosine resistance during combination therapy with caspofungin and flucytosine for Candida glabrata cystitis. Antimicrobial Agents and Chemotherapy, 60(1), 662–665. [181] ElBaradei, A. (2020). A decade after the emergence of Candida auris: What do we know? European Journal of Clinical Microbiology & Infectious Diseases, 39(9), 1617–1627. [182] Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., & Teixeira, M. C. (2015). New mechanisms of flucytosine resistance in c. glabrata unveiled by a chemogenomics analysis in s. cerevisiae. PloS one, 10(8), e0135110. [183] (SGD), S. G. D. (n.d.[c]). Fcy1 / ypr062w overview. https://www.yeastgenome.org/locus/S000006266 (accessed: 20.05.2022 [184] (SGD), S. G. D. (n.d.[d]). Fcy2 / yer056c overview. https://www.yeastgenome.org/locus/S000000858 (accessed: 20.05.2022 [185] Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018). Genomic epidemiology of the uk outbreak of the emerging human fungal pathogen Candida auris. Emerging microbes & infections, 7(1), 1–12. [186] Jacobs, S. E., Jacobs, J. L., Dennis, E. K., Taimur, S., Rana, M., Patel, D., Gitman, M., Patel, G., Schaefer, S., Iyer, K., et al. (2022). Candida auris pan-drug-resistant to four classes of antifungal agents. Antimicrobial Agents and Chemotherapy, e00053–22. [187] Berman, J., & Krysan, D. J. (2020). Drug resistance and tolerance in fungi. Nature Reviews Microbiology, 18(6), 319–331. [188] Delarze, E., & Sanglard, D. (2015). Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resistance Updates, 23, 12–19. [189] O’Kane, C. J., & Hyland, E. M. (2019). Yeast epigenetics: The inheritance of histone modification states. Bioscience Reports, 39(5). [190] Pristov, K., & Ghannoum, M. (2019). Resistance of Candida to azoles and echinocandins worldwide. Clinical Microbiology and Infection, 25(7), 792–798. [191] Panackal, A. A., Gribskov, J. L., Staab, J. F., Kirby, K. A., Rinaldi, M., & Marr, K. A. (2006). Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. Journal of Clinical Microbiology, 44(5), 1740–1743. [192] Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005). Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrobial agents and chemotherapy, 49(2), 668–679. [193] Schuetzer-Muehlbauer, M., Willinger, B., Krapf, G., Enzinger, S., Presterl, E., & Kuchler, K. (2003). The Candida albicans cdr2p atp-binding cassette (abc) transporter confers resistance to caspofungin. Molecular microbiology, 48(1), 225–235. 94 [194] Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014). Role of fks mutations in Candida glabrata: Mic values, echinocandin resistance, and multidrug resistance. Antimicrobial agents and chemotherapy, 58(8), 4690–4696. [195] Kelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995). Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8, 24 (28)-dien-3β, 6α-diol. Biochemical and biophysical research communications, 207(3), 910–915. [196] Hull, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G., Kelly, D. E., & Kelly, S. L. (2012). Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin b. Antimicrobial agents and chemotherapy, 56(8), 4223–4232. [197] Douglas, C., D’ippolito, J., Shei, G., Meinz, M., Onishi, J., Marrinan, J., Li, W., Abruzzo, G., Flattery, A., Bartizal, K., et al. (1997). Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3-beta-d-glucan synthase inhibitors. Antimicrobial agents and chemotherapy, 41(11), 2471–2479. [198] Picard, D. (2002). Heat-shock protein 90, a chaperone for folding and regulation. Cellular and Molecular Life Sciences CMLS, 59(10), 1640–1648. [199] Cowen, L. E. (2009). Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS pathogens, 5(8), e1000471. [200] Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009). Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS pathogens, 5(7), e1000532. [201] LaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. L., Perfect, J. R., & Cowen, L. E. (2010). Pkc signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of mkc1, calcineurin, and hsp90. PLoS pathogens, 6(8), e1001069. [202] Sreedhar, A. S., Mihály, K., Pató, B., Schnaider, T., Steták, A., Kis-Petik, K., Fidy, J., Simonics, T., Maráz, A., & Csermely, P. (2003). Hsp90 inhibition accelerates cell lysis: Anti-hsp90 ribozyme reveals a complex mechanism of hsp90 inhibitors involving both superoxide-and hsp90- dependent events. Journal of Biological Chemistry, 278(37), 35231–35240. [203] Lin, J., Zangi, M., Kumar, T. V. N. H., Shakar Reddy, M., Reddy, L. V. R., Sadhukhan, S. K., Bradley, D. P., Moreira-Walsh, B., Edwards, T. C., O’Dea, A. T., et al. (2021). Synthetic derivatives of ciclopirox are effective inhibitors of Cryptococcus neoformans. ACS omega, 6(12), 8477–8487. [204] Guembe, M., Guinea, J., Peláez, T., Torres-Narbona, M., & Bouza, E. (2007). Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrobial agents and chemotherapy, 51(9), 3457–3458. [205] Medić-Šarić, M., Maysinger, D., Movrin, M., & Dvoržak, I. (1980). Antibacterial and antifungal activities of nitroxoline mannich bases. Chemotherapy, 26(4), 263–267. [206] Pelletier, C., Prognon, P., & Bourlioux, P. (1995). Roles of divalent cations and ph in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrobial agents and chemotherapy, 39(3), 707–713. [207] Waugh, C. D. (2007). Agents acting on fungal cell membranes. [208] Prachayasittikul, V., Prachayasittikul, S., Ruchirawat, S., & Prachayasittikul, V. (2013). 8-hydroxyquinolines: A review of their metal chelating properties and medicinal applications. Drug design, development and therapy, 7, 1157. [209] Kresken, M., & Körber-Irrgang, B. (2014). In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in germany. Antimicrobial Agents and Chemotherapy, 58(11), 7019–7020. [210] Mamouei, Z., Alqarihi, A., Singh, S., Xu, S., Mansour, M. K., Ibrahim, A. S., & Uppuluri, P. (2018). Alexidine dihydrochloride has broad-spectrum activities against diverse fungal pathogens. Msphere, 3(5), e00539–18. [211] Wu, Y., Wu, M., Gao, J., & Ying, C. (2020). Antifungal activity and mode of action of miltefosine against clinical isolates of Candida krusei. Frontiers in Microbiology, 11, 854. [212] Wu, Y., Totten, M., Memon, W., Ying, C., & Zhang, S. X. (2020). In vitro antifungal susceptibility of the emerging multidrug-resistant pathogen Candida auris to miltefosine alone and in combination with amphotericin b. Antimicrobial agents and chemotherapy, 64(2), e02063–19. [213] Baddley, J. W., & Poppas, P. G. (2005). Antifungal combination therapy. Drugs, 65(11), 1461–1480. [214] Campitelli, M., Zeineddine, N., Samaha, G., & Maslak, S. (2017). Combination antifungal therapy: A review of current data. Journal of clinical medicine research, 9(6), 451. [215] Olson, J. A., Adler-Moore, J. P., Smith, P., & Proffitt, R. T. (2005). Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin b with caspofungin or micafungin. Antimicrobial agents and chemotherapy, 49(12), 4895–4902. [216] Barchiesi, F., Spreghini, E., Tomassetti, S., Giannini, D., & Scalise, G. (2007). Caspofungin in combination with amphotericin b against Candida parapsilosis. Antimicrobial agents and chemotherapy, 51(3), 941–945. [217] for Clinical Laboratory Standards, N. C., & Barry, A. L. (1999). Methods for determining bactericidal activity of antimicrobial agents: Approved guideline (Vol. 19). National Committee for Clinical Laboratory Standards Wayne, PA. 95 [218] Zarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I. (2009). Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against aspergillus fumigatus. Antimicrobial agents and chemotherapy, 53(6), 2654–2656. [219] Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004). Combination antifungal therapy for invasive aspergillosis. Clinical infectious diseases, 39(6), 797–802. [220] Nivoix, Y., Zamfir, A., Lutun, P., Kara, F., Remy, V., Lioure, B., Rigolot, J., Entz-Werle, N., Letscher-Bru, V., Waller, J., et al. (2006). Combination of caspofungin and an azole or an amphotericin b formulation in invasive fungal infections. Journal of Infection, 52(1), 67–74. [221] Shalit, I., Shadkchan, Y., Samra, Z., & Osherov, N. (2003). In vitro synergy of caspofungin and itraconazole against aspergillus spp.: Mic versus minimal effective concentration end points. Antimicrobial agents and chemotherapy, 47(4), 1416–1418. [222] Khalifa, H. O., Majima, H., Watanabe, A., & Kamei, K. (2021). In vitro characterization of twenty-one antifungal combinations against echinocandin-resistant and-susceptible Candida glabrata. Journal of Fungi, 7(2), 108. [223] Chen, Y.-L., Lehman, V. N., Averette, A. F., Perfect, J. R., & Heitman, J. (2013). Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or fk506 against Candida albicans. PLoS One, 8(3), e57672. [224] Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., & Burnie, J. (2003). Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal hsp90. Antimicrobial agents and chemotherapy, 47(7), 2208–2216. [225] Li, J., Coste, A. T., Bachmann, D., Sanglard, D., & Lamoth, F. (2022). Deciphering the mrr1/mdr1 pathway in azole resistance of Candida auris. Antimicrobial Agents and Chemotherapy, 66(4), e00067–22. [226] Vermitsky, J.-P., & Edlind, T. D. (2004). Azole resistance in Candida glabrata: Coordinate upregulation of multidrug transporters and evidence for a pdr1-like transcription factor. Antimicrobial Agents and Chemotherapy, 48(10), 3773–3781. [227] Whaley, S. G., Zhang, Q., Caudle, K. E., & Rogers, P. D. (2018). Relative contribution of the abc transporters cdr1, pdh1, and snq2 to azole resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy, 62(10), e01070–18. [228] Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014). UPC2 is universally essential for azole antifungal resistance in Candida albicans. Eukaryotic cell, 13(7), 933–946. [229] Branco, J., Ola, M., Silva, R., Fonseca, E., Gomes, N., Martins-Cruz, C., Silva, A., Silva-Dias, A., Pina-Vaz, C., Erraught, C., et al. (2017). Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance. Clinical Microbiology and Infection, 23(8), 575–e1. [230] Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012). Echinocandin resistance in Candida species: Mechanisms of reduced susceptibility and therapeutic approaches. Annals of Pharmacotherapy, 46(7-8), 1086–1096. [231] Dannaoui, E., Desnos-Ollivier, M., Garcia-Hermoso, D., Grenouillet, F., Cassaing, S., Baixench, M.-T., Bretagne, S., Dromer, F., Lortholary, O., Group, F. M. S., et al. (2012). Candida spp. with acquired echinocandin resistance, france, 2004–2010. Emerging infectious diseases, 18(1), 86. [232] Katiyar, S., Pfaller, M., & Edlind, T. (2006). Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrobial agents and chemotherapy, 50(8), 2892–2894. [233] Silva, L. N., Oliveira, S. S., Magalhães, L. B., Andrade Neto, V. V., Torres-Santos, E. C., Carvalho, M. D., Pereira, M. D., Branquinha, M. H., & Santos, A. L. (2020). Unmasking the amphotericin b resistance mechanisms in Candida haemulonii species complex. ACS Infectious Diseases, 6(5), 1273–1282. [234] Sagatova, A. A. (2021). Strategies to bette target fungal squalene monooxygenase. Journal of fungi (Basel), Vol.7 (1), p.1–13. [235] Morio, F., Pagniez, F., Besse, M., Gay-andrieu, F., Miegeville, M., & Le Pape, P. (2013). Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. International journal of antimicrobial agents, 42(5), 410–415. [236] Berkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015). Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrobial agents and chemotherapy, 59(10), 5942–5950. [237] Grossman, N. T., Pham, C. D., Cleveland, A. A., & Lockhart, S. R. (2015). Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a us surveillance system. Antimicrobial agents and chemotherapy, 59(2), 1030–1037. [238] Shivarathri, R., Jenull, S., Chauhan, M., Singh, A., Mazumdar, R., Chowdhary, A., Kuchler, K., & Chauhan, N. (2022). Comparative transcriptomics reveal possible mechanisms of amphotericin b resistance in Candida auris. Antimicrobial Agents and Chemotherapy, e02276–21. [239] Udekwu, K. I., & Weiss, H. (2018). Pharmacodynamic considerations of collateral sensitivity in design of antibiotic treatment regimen. Drug Design, Development and Therapy, 12, 2249. [240] Van Hasselt, J. C., & Iyengar, R. (2019). Systems pharmacology: Defining the interactions of drug combinations. Annual review of pharmacology and toxicology, 59, 21–40. [241] Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., & Levin, B. R. (2004). Pharmacodynamic functions: A multiparameter approach to the design of antibiotic treatment regimens. Antimicrobial agents and chemotherapy, 48(10), 3670–3676. 96 [242] Kochupurakkal, B. S., & Iglehart, J. D. (2013). Nourseothricin n-acetyl transferase: A positive selection marker for mammalian cells. PloS one, 8(7), e68509. [243] Cheung, H.-Y., Wong, M. M.-K., Cheung, S.-H., Liang, L. Y., Lam, Y.-W., & Chiu, S.-K. (2012). Differential actions of chlorhexidine on the cell wall of bacillus subtilis and Escherichia coli. PLoS One, 7(5), e36659. [244] Azad, G. K., & Tomar, R. S. (2014). Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways. Molecular biology reports, 41(8), 4865–4879. [245] Amagata, T. (2010). Natural products structural diversity-ii secondary metabolites: Sources, structures and chemical biology. Comprehensive Natural Products II, 2, 581–621. [246] McCARTHY, P. J., TROKE, P. F., & GULL, K. (1985). Mechanism of action of nikkomycin and the peptide transport system of Candida albicans. Microbiology, 131(4), 775–780. [247] Sonzogni-Desautels, K., Renteria Flores, A., Vasquez Camargo, F., Di Lenardo, T. Z., Mikhail, A., Arrowood, M. J., Fortin, A., & Ndao, M. (2015). Oleylphosphocholine (olpc) arrests cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice. Frontiers in microbiology, 6, 973. [248] Li, B., Flaveny, C. A., Giambelli, C., Fei, D. L., Han, L., Hang, B. I., Bai, F., Pei, X.-H., Nose, V., Burlingame, O., et al. (2014). Repurposing the fda-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PloS one, 9(7), e101969. [249] Ishii, I., Harada, Y., & Kasahara, T. (2012). Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Frontiers in oncology, 2, 137. [250] Bucchi, F., Cerletti, C., & de Gaetano, G. (1986). Inhibition of platelet thromboxane generation by suloctidil in man. Pathophysiology of Haemostasis and Thrombosis, 16(5), 362–368. [251] Gentilello, L. M., & Reed, R. L. (2008). Hypothermia and trauma. In Current therapy of trauma and surgical critical care (pp. 721–726). Elsevier Inc. [252] Gaba, B., Fazil, M., Khan, S., Ali, A., Baboota, S., & Ali, J. (2015). Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bulletin of Faculty of Pharmacy, Cairo University, 53(2), 147–159.